Characteristics of Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol or Other Triple Therapies in Japan: A Real-World Healthcare Claims Database Study (MITOS-AURA)
Many patients initiating triple therapy for COPD had concomitant asthma and had previously received ICS/LABA maintenance therapy. Patients prescribed BGF in the initial post-launch period were more likely to have a previous exacerbation history versus other cohorts, indicating more severe disease.
Authors
- Johann Castañeda-Sanabria
- Naoyuki Makita
- Hana Müllerová (ORCID: https://orcid.org/0000-0002-0949-0101)
- Ramzi Argoubi (ORCID: https://orcid.org/0000-0002-3171-0078)
- Koichiro Takahashi (ORCID: https://orcid.org/0000-0003-0461-5072)
- Seham Issa (ORCID: https://orcid.org/0000-0002-1854-1839)
- Grégoire Nowacki
- Isao Matsumoto
- Yuri Yoshida
Institutions
- AstraZeneca (United Kingdom) (GB)
- Saga University (JP)
- AstraZeneca (France) (FR)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s12325-024-02994-8
- Citations
- 2
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- AstraZeneca